Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro. Lilly claims Mochi ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Writer-Reporter at PEOPLE. She ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed ...

Share on Pinterest People who rely on compounded GLP-1 drugs say they might not be able to afford brand-name versions, which are often not covered by insurance. Iuliia Burmistrova/Getty Images The FDA ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Katie Palmer covers ...

When Chris Spears' pharmacy didn't have the obesity drug his doctor prescribed in 2023, he found another option while scrolling on Facebook. His feed was full of advertisements for alternatives to the ...

Compounded alternatives to Zepbound are on the way out. When Christina and Jackson Agar used to get a pizza, they’d polish it off the same night. Things are different now that they’re both taking an ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt to ...

When Christina and Jackson Agar used to get a pizza, they'd polish it off the same night. Things are different now that they're both taking an obesity drug. "We recently ordered a pizza and we ate ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...